(NasdaqGM:CAPT), MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) — Captivision Inc. (“Captivision” or the “Company”) (Nasdaq: CAPT), a pioneering manufacturer and global LED provider, announced continuing strategic transformation and a resulting management change in preparation. As previously announced, the Company is exploring strategic options for Captivision Korea, its wholly owned subsidiary. This exploration has extended to […]

(NASDAQ:OLMA), SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference

(NasdaqGM:LAFAU),(NasdaqGM:LAFA),(NasdaqGM:LAFAR), Paris, France, Nov. 21, 2025 (GLOBE NEWSWIRE) — LaFayette Acquisition Corp. (the “Company”) announced today that, commencing on or about Wednesday, November 26, 2025, holders of the units sold in the Company's initial public offering may elect to separately trade the ordinary shares and rights included in the units. The ordinary shares and rights

(NASDAQ:RARE), NOVATO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 18,180 restricted stock units of the company's common stock to 12 newly hired non-executive officers of the company. The

(NYSE:TEVA),(TASE:TEVA.TA),(TASE:TEVA), TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management will present at three upcoming investor conferences in December as follows: 8th Annual Evercore Healthcare ConferenceWednesday, December 3, 2025, at 8:20 A.M.

Opendoor Distributes Special Dividend of Tradable Warrants to Shareholders GlobeNewswire November 21, 2025 SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) — Opendoor Technologies Inc. (Nasdaq: OPEN) (“Opendoor” or the “Company”) today announced the distribution of warrants to purchase the Company's common stock to its registered stockholders and certain convertible noteholders on Friday, November 21, 2025

LaFayette Acquisition Corp. Announces the Separate Trading of Its Ordinary Shares and Rights, Commencing on or About November 26, 2025 GlobeNewswire November 21, 2025 Paris, France, Nov. 21, 2025 (GLOBE NEWSWIRE) — LaFayette Acquisition Corp. (the “Company”) announced today that, commencing on or about Wednesday, November 26, 2025, holders of the units sold in the

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire November 21, 2025 NOVATO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 18,180 restricted stock units of the company's

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December GlobeNewswire November 21, 2025 TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO,

SNDL Announces Renewal of Share Repurchase Program GlobeNewswire November 21, 2025 EDMONTON, Alberta, Nov. 21, 2025 (GLOBE NEWSWIRE) — SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) (“SNDL” or the “Company“) announced today that it has received approval from the Canadian Securities Exchange (“CSE“) for the renewal of its share repurchase program (the “Share Repurchase Program“). The